How India Exports Probiotics to the World

Probiotics, classified under HS Code 30029090, are not listed in the FDA's Orange Book, indicating a lack of approved New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) for these products. This absence suggests that probiotics are not recognized as approved drug products by the FDA. Consequently, they are typically marketed in the United States as dietary supplements rather than pharmaceuticals. The regulatory pathway for dietary supplements is distinct from that of drugs; manufacturers are responsible for ensuring product safety and labeling compliance but are not required to obtain FDA approval before marketing. Given that 23.8% of India's probiotic exports are destined for the U.S., Indian exporters must adhere to the FDA's dietary supplement regulations, including the Dietary Supplement Health and Education Act (DSHEA) of 1994, to ensure market compliance.

In the European Union and the United Kingdom, probiotics are generally classified as food supplements. The European Food Safety Authority (EFSA) evaluates health claims associated with these products. To date, EFSA has not approved any health claims for probiotics, meaning that marketing materials cannot assert specific health benefits. Manufacturers must comply with EU regulations on food safety, labeling, and health claims, including Regulation (EC) No 1924/2006 on nutrition and health claims made on foods. In the UK, post-Brexit, similar standards are maintained under the Nutrition and Health Claims (England) Regulations 2007. With 10.8% of India's probiotic exports directed to Italy and 3.8% to Germany, Indian exporters must ensure their products meet these stringent EU and UK regulatory requirements.

Probiotics are not included in the World Health Organization's Model List of Essential Medicines, indicating they are not considered essential for basic health systems. Consequently, there are no WHO prequalification standards specifically for probiotics. However, manufacturers often refer to international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), for quality specifications. Adherence to these standards ensures product quality and facilitates acceptance in various international markets.

In India, probiotics are typically classified as dietary supplements or nutraceuticals rather than pharmaceuticals. As such, they do not fall under the purview of the Drugs and Cosmetics Act's Schedules H, H1, or X, which govern prescription medications. The Food Safety and Standards Authority of India (FSSAI) regulates these products under the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Functional Food, and Novel Food) Regulations, 2016. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) to comply with export requirements.

The absence of probiotics in the FDA's Orange Book suggests there are no active patents or exclusivity periods associated with these products in the U.S. market. This lack of patent protection indicates a competitive market environment, allowing multiple manufacturers to produce and sell probiotic products without infringing on proprietary rights.

In August 2025, the FDA issued updated guidance on the labeling of dietary supplements, emphasizing the need for clear differentiation between structure/function claims and disease claims to prevent misleading consumers. This development is particularly relevant for probiotic manufacturers aiming to market their products in the U.S.

In November 2025, the European Commission published a report evaluating the safety and efficacy of probiotics in food products. The report concluded that while probiotics are generally safe for consumption, there is insufficient evidence to substantiate many health claims, reinforcing the need for compliance with existing EU regulations on health claims.

In January 2026, the FSSAI introduced new guidelines for the manufacturing and labeling of probiotics in India, aligning domestic standards more closely with international norms. These guidelines aim to enhance product quality and facilitate smoother export processes for Indian manufacturers.

In February 2026, the Australian Therapeutic Goods Administration (TGA) updated its list of permitted ingredients for listed medicines, including specific strains of probiotics. This update affects Indian exporters, as Australia accounts for 25.8% of India's probiotic exports.

In March 2026, the U.S. Department of Agriculture (USDA) reported a 5% increase in the import of dietary supplements, including probiotics, over the previous year. This trend indicates a growing market demand in the U.S., presenting opportunities for Indian exporters.

India's pharmaceutical industry, including the probiotics sector, heavily relies on imports for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). Approximately 70% of APIs are sourced from China, with some critical APIs being entirely dependent on Chinese imports. This dependency exposes the supply chain to risks such as geopolitical tensions, trade disputes, and production disruptions in China. For instance, during the COVID-19 pandemic, factory shutdowns in China led to immediate shortages and price surges for essential drugs in India.

To mitigate these vulnerabilities, the Indian government launched the Production Linked Incentive (PLI) scheme in 2020, aiming to boost domestic manufacturing of APIs and KSMs. By November 2024, two greenfield plants were inaugurated under this scheme to produce critical molecules like Penicillin G and Clavulanic Acid, which had not been manufactured domestically for over two decades. These initiatives are expected to reduce import dependence by half for key pharmaceutical ingredients.

Our proprietary trade data indicates a significant concentration in India's probiotics export market. The top five exporters account for 98.5% of total exports, with UNIQUE BIOTECH LIMITED alone holding a 71.2% share. Such high supplier concentration poses substantial risks, including potential supply disruptions and limited bargaining power for buyers.

The PLI scheme has been instrumental in encouraging diversification and reducing single-source dependency. By incentivizing domestic production of APIs and KSMs, the scheme aims to create a more resilient supply chain. As of September 2025, the PLI schemes across various sectors have resulted in significant investments and measurable increases in production and employment.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can disrupt supply chains. For example, heightened US-China trade tensions have previously led to increased tariffs and trade barriers, affecting the availability and cost of pharmaceutical ingredients. Additionally, the FDA has issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practices (cGMP), highlighting ongoing quality concerns and the potential for supply disruptions.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source.

• Strengthen Domestic Manufacturing: Leverage government incentives like the PLI scheme to invest in local production of APIs and KSMs.

• Enhance Quality Control: Implement stringent quality assurance protocols to address cGMP compliance issues and ensure product integrity.

• Monitor Geopolitical Developments: Stay informed about international trade policies and geopolitical events that may impact supply chains.

• Develop Contingency Plans: Establish robust risk management strategies, including alternative shipping routes and inventory buffers, to mitigate potential disruptions.

RISK_LEVEL: MEDIUM